Abstract: There is provided a client device including a storage section which stores content data, a control section which acquires content identification information for identifying the content data stored in the storage section, and a transmission section which transmits, to a server device, a registration request including user identification information for identifying a user who uses the client device and the content identification information acquired by the control section, and which, when the server device holds the content data identified by the content identification information, causes the server device to hold information obtained by associating the user identification information with the content identification information as user-specific registration information.

Abstract: The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which has an excellent inhibitory action on the ATPase activity of a TIP48/TIP49 complex and as such, is useful for the treatment of tumors. [Solution] The present invention provides a compound having a structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the present specification.

Abstract: An electronic processing system, and a method of operation thereof, including: a verification module for connecting to a gaming network using a user account and for associating a verified account with the user account by performing a single click operation on a following button to follow the verified account; a recommendation module, coupled to the verification module, for receiving a comment about the verified account in a comment entry control; and a display module, coupled to the recommendation module, for displaying the comment in a comments list display.

Abstract: Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1): [wherein, Ar which is a partial structure in the general formula (1) represents a phenyl group or a naphthyl group; R1a and R1b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; R2a and R2b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; A represents a single bond, an oxygen atom, or the like; B represents a single bond, a C1-C4 alkanediyl group, or the like; Z represents a carboxyl group or a tetrazolyl group; and m represents an integer of 1 to 3] or a pharmacologically acceptable salt thereof.

Abstract: There is provided a client device including a storage section which stores content data, a control section which acquires content identification information for identifying the content data stored in the storage section, and a transmission section which transmits, to a server device, a registration request including user identification information for identifying a user who uses the client device and the content identification information acquired by the control section, and which, when the server device holds the content data identified by the content identification information, causes the server device to hold information obtained by associating the user identification information with the content identification information as user-specific registration information.

Abstract: There is provided a client device including a storage section which stores content data, a control section which acquires content identification information for identifying the content data stored in the storage section, and a transmission section which transmits, to a server device, a registration request including user identification information for identifying a user who uses the client device and the content identification information acquired by the control section, and which, when the server device holds the content data identified by the content identification information, causes the server device to hold information obtained by associating the user identification information with the content identification information as user-specific registration information.

Abstract: Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1): [wherein, Ar which is a partial structure in the general formula (1) represents a phenyl group or a naphthyl group; R1a and R1b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; R2a and R2b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; A represents a single bond, an oxygen atom, or the like; B represents a single bond, a C1-C4 alkanediyl group, or the like; Z represents a carboxyl group or a tetrazolyl group; and m represents an integer of 1 to 3] or a pharmacologically acceptable salt thereof.

Abstract: There is provided a client device including a storage section which stores content data, a control section which acquires content identification information for identifying the content data stored in the storage section, and a transmission section which transmits, to a server device, a registration request including user identification information for identifying a user who uses the client device and the content identification information acquired by the control section, and which, when the server device holds the content data identified by the content identification information, causes the server device to hold information obtained by associating the user identification information with the content identification information as user-specific registration information.

Abstract: Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1): [wherein, Ar which is a partial structure in the general formula (1) represents a phenyl group or a naphthyl group; R1a and R1b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; R2a and R2b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; A represents a single bond, an oxygen atom, or the like; B represents a single bond, a C1-C4 alkanediyl group, or the like; Z represents a carboxyl group or a tetrazolyl group; and m represents an integer of 1 to 3] or a pharmacologically acceptable salt thereof.

Abstract: The present invention relates to a biaryl derivative or a pharmacologically acceptable salt thereof having an excellent collagen-synthesis inhibition activity. A biaryl derivative having a structure represented by the following General Formula (I) or a pharmacologically acceptable salt thereof: wherein R1 represents a C6-C10 aryl group which is substituted with one to three group(s) each independently selected from the group consisting of a group defined by formula R-L-, a di-(C1-C6 alkyl)amino group, a di-(C1-C6 alkyl)aminosulfonyl group, a hydroxyaminocarbonyl group, and a halogen atom, and so on; R represents a C1-C6 alkyl group, and so on; L represents a sulfonyl group, an aminosulfonyl group, or a sulfonylamino group, and so on; R2 represents a hydrogen atom, and so on; A represents a group defined by formula (II), (III), or (IV); R3 represents a C1-C6 alkyl group, and so on; and R4 represents a C1-C6 alkyl group, and so on.